BR0213103A - Método para tratamento de infecção pelo vìrus da hepatite com um perfil de liberação de interferon multifásico - Google Patents

Método para tratamento de infecção pelo vìrus da hepatite com um perfil de liberação de interferon multifásico

Info

Publication number
BR0213103A
BR0213103A BR0213103-0A BR0213103A BR0213103A BR 0213103 A BR0213103 A BR 0213103A BR 0213103 A BR0213103 A BR 0213103A BR 0213103 A BR0213103 A BR 0213103A
Authority
BR
Brazil
Prior art keywords
multiphase
virus infection
hepatitis virus
treating hepatitis
antiviral agent
Prior art date
Application number
BR0213103-0A
Other languages
English (en)
Inventor
Gary Visor
Peter Van Vlasselaer
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of BR0213103A publication Critical patent/BR0213103A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MéTODO PARA TRATAMENTO DE INFECçãO PELO VìRUS DA HEPATITE COM UM PERFIL DE LIBERAçãO DE INTERFERON MULTIFáSICO". A presente invenção refere-se a métodos para tratar infecção pelo vírus da hepatite. Os métodos envolvem de modo geral a administração de uma composição compreendendo um agente antiviral em um regime de dosagem que alcança um perfil de concentração sérica multifásica do agente antiviral. O regime de dosagem inclui eventos de dosagem que são menos freq³entes do que com as terapias para hepatite atualmente disponíveis. O perfil de concentração sérica multifásica do agente antiviral que é atingido usando os métodos da invenção causam uma rápida queda inicial do título viral, seguida por uma redução adicional do título viral durante o tempo, para obter alcançar uma resposta viral sustentada.
BR0213103-0A 2001-10-05 2002-09-26 Método para tratamento de infecção pelo vìrus da hepatite com um perfil de liberação de interferon multifásico BR0213103A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32774401P 2001-10-05 2001-10-05
PCT/US2002/030837 WO2003030923A1 (en) 2001-10-05 2002-09-26 Method of treating hepatitis virus infection with a multiphasic interferon delivery profile

Publications (1)

Publication Number Publication Date
BR0213103A true BR0213103A (pt) 2004-09-21

Family

ID=23277854

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213103-0A BR0213103A (pt) 2001-10-05 2002-09-26 Método para tratamento de infecção pelo vìrus da hepatite com um perfil de liberação de interferon multifásico

Country Status (15)

Country Link
US (2) US20050063949A1 (pt)
EP (1) EP1450838A4 (pt)
JP (1) JP2005508943A (pt)
KR (1) KR20050030886A (pt)
CN (1) CN1738635A (pt)
AR (1) AR036728A1 (pt)
BR (1) BR0213103A (pt)
CA (1) CA2460690A1 (pt)
HU (1) HUP0401818A2 (pt)
IL (1) IL160965A0 (pt)
MX (1) MXPA04003238A (pt)
NO (1) NO20041814L (pt)
PL (1) PL369870A1 (pt)
WO (1) WO2003030923A1 (pt)
ZA (1) ZA200402236B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2587002A (en) 2000-11-03 2002-05-15 Biomedicines Inc Method for short-term and long-term drug dosimetry
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP1561470A1 (en) * 2003-06-20 2005-08-10 Innogenetics N.V. HCV vaccines comprising the envelope-1 (E1) protein or the corresponding DNA and at least one antiviral agent
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
EP2049081B1 (en) 2006-08-09 2012-11-14 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
HRP20130259T1 (hr) 2007-04-23 2013-04-30 Intarcia Therapeutics, Inc. Suspenzijske formulacije inzulinotropnih peptida i njihove uporabe
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
CN101801405A (zh) 2007-08-07 2010-08-11 先进科技及再生医学有限责任公司 包含于酸性水溶液中的gdf-5的蛋白质配方
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
EP2286359A2 (en) * 2008-03-27 2011-02-23 Medtronic, Inc. Method and system to define patient specific therapeutic regimens by means of pharmacokinetic and pharmacodynamic tools
US20090246171A1 (en) * 2008-03-27 2009-10-01 Van Antwerp William P Automatic system for dose control in treating hepatitis c using infusion pumps
BRPI0911048A2 (pt) 2008-04-14 2015-12-29 Atrm Llc formulações líquidas tamponadas de gdf-5
US9561214B2 (en) * 2008-10-16 2017-02-07 Array Biopharma Inc. Method of treatment using inhibitors of mitosis
US20110027229A1 (en) * 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
SMT201700583T1 (it) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
WO2011159930A2 (en) 2010-06-16 2011-12-22 Medtronic, Inc. Damping systems for stabilizing medications in drug delivery devices
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
DE112012002748T5 (de) 2011-10-21 2014-07-31 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN103071147A (zh) * 2011-10-26 2013-05-01 麦德托尼克公司 干扰素-α向乙型肝炎感染的患者的连续皮下施用
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5980884A (en) * 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6455051B1 (en) * 1997-10-13 2002-09-24 Otsuka Pharmaceutical Co., Ltd. Ameliorant for hepatitis C therapeutic effect and application thereof
US6824768B2 (en) * 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
US6245740B1 (en) * 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
AU2587002A (en) * 2000-11-03 2002-05-15 Biomedicines Inc Method for short-term and long-term drug dosimetry

Also Published As

Publication number Publication date
MXPA04003238A (es) 2004-07-08
KR20050030886A (ko) 2005-03-31
AR036728A1 (es) 2004-09-29
PL369870A1 (en) 2005-05-02
US20090196853A1 (en) 2009-08-06
CN1738635A (zh) 2006-02-22
US20050063949A1 (en) 2005-03-24
EP1450838A1 (en) 2004-09-01
HUP0401818A2 (hu) 2004-11-29
EP1450838A4 (en) 2005-09-28
ZA200402236B (en) 2005-03-22
WO2003030923A1 (en) 2003-04-17
JP2005508943A (ja) 2005-04-07
NO20041814L (no) 2004-06-11
IL160965A0 (en) 2004-08-31
CA2460690A1 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
BR0213103A (pt) Método para tratamento de infecção pelo vìrus da hepatite com um perfil de liberação de interferon multifásico
BR9811121A (pt) Produto, composição farmacêutica, e uso de um produto
BR0111732A (pt) Prodrogas de 2-deóxi-beta-l-nucleosìdeos
NO20073151L (no) Fremgangsmater og sammensetninger for a behandle hepatitt C virus
BR0208652A (pt) Composição parenteral reconstituìvel contendo um inibidor de cox-2
EA201000085A1 (ru) dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ
EA200201263A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
BRPI0516825A (pt) inibição da protease ns3-ns4a do vìrus da hepatite c (vhc)
CY1110437T1 (el) Χρηση παραγωγων καστανοσπερμινης για την θεραπεια της ηπατιτιδας c
EA200100168A1 (ru) Схема лечения при введении фенилацетилглутамина, фенилацетилизоглутамина и/или фенилацетата
BR0316244A (pt) Vacina de polinucleotìdeo, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina de polinucleotìdeo
ATE481135T1 (de) Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen
WO2005013917A3 (en) Combination therapy for treating alphavirus infection and liver fibrosis
DK1284720T3 (da) L-FMAU til behandling af hepatitis delta-virusinfektion
BR0311223A (pt) Método para o uso de derivados de piranindol para tratar infecção pelo vìrus da hepatite c
BR0212917A (pt) Método para tratamento de infecção de vìrus da hepatite c em pacientes que não responderam a tratamento
ES2105923B1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
Lewis Effects of Epsilon Amino Caproic Acid (EACA) on Survival of Fibrinogen I131 and on Fibrinolytic and Coagulation Factors in Dogs.
UA95299C2 (ru) Профилактический или терапевтический агент против вирусного заболевания, вызванного вирусом гепатита с
AR036698A1 (es) Metodo para el tratamiento de la infeccion por virus de hepatitis c en pacientes sin respuesta a tratamiento
BR9908540A (pt) Molécula de ácido nucleico recombinante, célula hospedeira recombinante, composição farmacêutica, e, processo para induzir uma resposta imune contra vìrus de hepatite c em um humano não infectado por vìrus de hepatite c, para imunizar um humano suscetìvel a vìrus de hepatite c, e para tratar um humano que é infectado com vìrus de hepatite c
WO2002087600A8 (de) Verwendung von phyllanthusbestandteilen zur behandlung oder prophylaxe von infekten durch hepatitis b-viren
WO2005016288A3 (en) Methods and compositions for treatment of viral diseases
NO953473L (no) Fremgangsmåte for behandling av hepatitt C i individer som er ikke-respondere overfor interferonbehandling
CY1106388T1 (el) Θepαπεια ηπατιτιδας c με θυμοσινη, ιντepφepονη και ριβαβιρινη

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A E 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.